Clinical Trial

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Trial Details
NCT Number NCT07656727
Lead Sponsor BioAge Labs, Inc.
Conditions Obesity and Cardiovascular Risk
Enrollment 160 participants
Start Date 2026-06-11
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-18